Skip to content

Perioperative decongestion and hemostasis, and postoperative analgesia for FESS after intranasal application of cocaine, tetracaine-oxymetazoline or ropivacaine-oxymetazoline

Perioperative decongestion and hemostasis, and postoperative analgesia for FESS after intranasal application of cocaine, tetracaine-oxymetazoline or ropivacaine-oxymetazoline - Decongestion for FESS after application of intranasal medication

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON32081
Enrollment
90
Registered
2008-10-17
Start date
2008-07-01
Completion date
Unknown
Last updated
2024-05-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

nasal polyposis swollen mucous membrane of the nose

Interventions

The surgeon places intranasal gauzes with cocaine, ropivacaine-oxymetazolin or tetracaine-oxymetazolin during 15 minutes

Sponsors

Canisius Wilhelmina Ziekenhuis
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: First FESS-operation Age: >=18years ASA 1-3 (patient classification as by the American Society of Anesthesiology) Competent and the Dutch language understanding in word and reading

Exclusion criteria

Exclusion criteria: Perioperative intake anticoagulants Chronic painsyndrom Pregnancy Allergy for lokal anesthetics Psychiatric disorder with disease of reality experience

Design outcomes

Primary

MeasureTime frame
The surgeon will range the operative site for decongestion and hemostasis using a numeric rating scale (NRS 0-10). The perooperative bloodloss, the amount of extra ultracaine-epinefrine injections and the operation-time will be noted Pain (+medication) nausea/vomiting (+medication), heartrate and bloodpressure, drowsiness and bloodloss will be registrated till 24 hours postoperatively (t=0,1 2, 6, 12, 18 and 24h)

Secondary

MeasureTime frame
Satisfaction of the patient about the treatment Complications

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)